PURE Bioscience

PURE Bioscience

OOTC:PURE
0.06
USD
-0.01
(-14.29%)
-0.02EPS
8.32MMarket Cap

Total Valuation

USD

As of July 31, 2026, PURE Bioscience carries a market capitalization of 8.32M, placing it among publicly traded companies globally. Its enterprise value stands at 14.35M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.32M
Enterprise Value14.35M

Share Statistics

As of July 31, 2026, PURE Bioscience has 130.02M shares outstanding.

Shares Outstanding130.02M

Valuation Ratios

These figures are as of July 31, 2026. The price-to-sales ratio is 3.21, and the price-to-book ratio stands at -1.30.

PS Ratio3.21
PB Ratio-1.30
P/TBV Ratio-1.30
P/FCF Ratio-4.28
P/OCF Ratio-4.28

Enterprise Valuation

These figures are as of July 31, 2026. The EV/Sales ratio of 6.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 14.35M versus a market cap of 8.32M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales6.19

Financial Position

As of July 31, 2026, PURE Bioscience maintains a current ratio of 0.27, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -103.17, indicating conservative leverage, while an interest coverage ratio of -5.11 demonstrates limited ability to service its debt obligations.

Current Ratio0.27
Quick Ratio0.21
Debt / Equity-103.17
Debt / EBITDA-3.17
Interest Coverage-5.11

Financial Efficiency

USD

These figures cover the twelve months ended July 31, 2026. The company generates approximately 197,276.60 in revenue per employee across its workforce of 11.75, a quick read on workforce productivity versus industry peers.

Revenue Per Employee197,276.60
Employee Count11.75

Stock Price Statistics

USD

As of the close on November 16, 2026, PURE Bioscience's stock has gained approximately 10.40% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.07.

52-Week Price Change10.40%
50-Day Moving Average0.07
200-Day Moving Average0.07

Income Statement

USD

Over the twelve months ended July 31, 2026, PURE Bioscience generated 2.32M in revenue and converted that into -2.48M in net income, yielding earnings per share of -0.02. EBITDA reached -2.08M, while operating income came in at -2.08M.

Revenue2.32M
Gross Profit1.33M
Operating Income-2.08M
Pretax Income-2.48M
Net Income-2.48M
EBITDA-2.08M
EBIT-2.08M
Earnings Per Share (EPS)-0.02

Balance Sheet

USD

As of July 31, 2026, PURE Bioscience holds 569,000.00 in cash and equivalents against 6.60M in total debt, resulting in a net debt position of 6.03M. Total book value stands at -6.40M, with working capital of -3.19M providing operational flexibility.

Cash & Cash Equivalents569,000.00
Total Debt6.60M
Net Debt6.03M
Equity (Book Value)-6.40M
Book Value Per Share-0.05
Working Capital-3.19M

Cash Flow

USD

PURE Bioscience produced -1.74M in operating cash flow over the twelve months ended July 31, 2026.

Operating Cash Flow-1.74M
Free Cash Flow-1.74M
FCF Per Share-0.01

Margins

Over the twelve months ended July 31, 2026, PURE Bioscience posted a gross margin of 57.20, reflecting its pricing power and cost economics. The operating margin of -89.86 and net profit margin of -107.12 provide insight into operational efficiency.

Gross Margin57.20
Operating Margin-89.86
Pretax Margin-107.12
Profit Margin-107.12
EBITDA Margin-89.73

Dividends & Yields

These figures cover the twelve months ended July 31, 2026. Free cash flow yield is negative at -23.38: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -23.71, meaning PURE Bioscience raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-23.71
FCF Yield-23.38

Stock Splits

PURE Bioscience's most recent stock split took place on August 15, 2012 with a 8:1 split ratio.

Last Split Date8/15/2012
Split Ratio8:1

Scores

As of July 31, 2026, PURE Bioscience has an Altman Z-Score of -172.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-172.39